Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
about
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkersThe past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular eventsBiological markers of Alzheimer's diseaseTesting the right target and right drug at the right stageClinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkersA window into the heterogeneity of human cerebrospinal fluid Aβ peptidesUshering in the study and treatment of preclinical Alzheimer diseaseThe BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical reviewMild cognitive impairment: diagnosis, longitudinal course, and emerging treatmentsMild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's diseaseThe Alzheimer's disease neuroimaging initiative: progress report and future plansHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeTracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkersMeditation and Music Improve Memory and Cognitive Function in Adults with Subjective Cognitive Decline: A Pilot Randomized Controlled Trial.Meditation as a therapeutic intervention for adults at risk for Alzheimer's disease - potential benefits and underlying mechanisms.Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy.Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer diseaseComparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database.Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly.Total and phosphorylated tau protein as biological markers of Alzheimer's disease.Preoperative cerebrospinal fluid β-Amyloid/Tau ratio and postoperative delirium.Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sampleCerebrospinal fluid biomarkers of Alzheimer's disease.Differential distribution of subjective and objective cognitive impairment in the population: a nation-wide twin-study.Memory concerns, memory performance and risk of dementia in patients with mild cognitive impairment.Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment.Soluble amyloid-β levels and late-life depressionCerebrospinal fluid analysis should be considered in patients with cognitive problemsLessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease.Biological markers and Alzheimer disease: a canadian perspectivePlasma DYRK1A as a novel risk factor for Alzheimer's disease.Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's diseaseAssessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions.Prospective memory on a novel clinical task in older adults with mild cognitive impairment and subjective cognitive decline
P2860
Q24193707-FD387D00-F445-4537-89A0-B85D5DA41C49Q26745508-733074BF-AC08-42F0-BF8A-09009411A080Q26781635-B917534E-6162-48E8-A412-ED6A772B89C8Q26823847-7A23A2A5-A812-4427-AD91-C017E761BF34Q26864854-51C0CDFD-2956-4952-89FE-41D81832FE6BQ27008249-EE33E0A5-7B39-4AC6-B629-08D53C485B6DQ27010785-0F25AD62-3D0F-48EF-AB2A-8F179202D2FEQ27014791-642D8E67-8A31-4849-BACC-1EDB61B1D3ABQ27022753-F8E2305C-DB17-4D9A-B222-36D512AE62E0Q27026362-6FC2DEC6-3154-4EDE-A403-FC5A86CD6EEBQ27027319-5F4E04F9-B0AE-4361-BAC4-BCF6FAFC0286Q28749585-D878ABF3-6BB8-467C-B2C7-FF5945336195Q29614407-AD57C1E4-588F-4A20-AA8F-888082281869Q29620245-B000CC6C-E7A0-4EC0-88BA-89ECAB5E460CQ30274953-B68AF88D-0E8F-48B7-B145-724D90656CC2Q30413222-D990619A-B67E-41CA-9932-23EA6DFA7050Q30651551-FB3B0C02-1484-4C58-AF30-CB77C8D7EA72Q30668465-702788E1-6BCE-40AD-8CD8-87CCF7C8756AQ30996727-68B70BD1-E1E1-41C6-8D39-362F1B67B4FAQ33556068-56BCC0D4-6E4D-41AB-A50F-86A2C67CD5D2Q33560183-287B6896-7E35-4FC5-B633-4EA498123EA1Q33604453-B268BBA0-B389-4DF4-8C80-E600BCAB1A5BQ33616120-B9C386A6-E9D2-420A-9CA9-A15FD640B735Q33624674-59A0D3FB-7C1E-40A9-84E7-122B2F3F52B6Q33644582-53C75E0B-4B09-459B-B9EF-D5C9B5F016E7Q33687554-5397BBE9-C2B1-4A47-8E4E-FA7F5AC956DFQ33726122-6B12C2AF-FE3E-47FC-BB9D-802977D45313Q33757828-F8FFAB42-4CB2-4ECA-B7BE-923DA423D894Q33777252-EC772331-9712-431F-9D6F-A9A9D9EB2DDDQ33895227-5FB5F7A8-F39C-480B-880C-E73392D4BFE8Q33924292-0D507141-8B43-46A1-BCC6-C81E68711702Q33933220-7B5F6997-56B0-4B8D-8F2E-2D065169B181Q34026659-8B629C9C-1B71-4AB7-8DF6-69E89AE12BC9Q34043074-D23981C6-E80F-4F86-A61C-F0CDF8176FC5Q34089784-828496A9-9C5A-4D05-BC18-D0B9FA590957Q34113379-CA980251-B9E7-4988-A13C-3B72416FEF20Q34162069-4D699157-CF93-41A7-B88A-4409B2F365CDQ34247849-7D3E7BDE-01A0-4A5D-8A70-B6CB1B2F7311Q34318022-B435DB65-BAFC-41AA-88AC-2918E771CA67Q34479022-663B3ACC-2C19-4705-99EA-13DBB65E5AA1
P2860
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Prevalence and prognostic valu ...... y: a prospective cohort study.
@en
Prevalence and prognostic valu ...... y: a prospective cohort study.
@nl
type
label
Prevalence and prognostic valu ...... y: a prospective cohort study.
@en
Prevalence and prognostic valu ...... y: a prospective cohort study.
@nl
prefLabel
Prevalence and prognostic valu ...... y: a prospective cohort study.
@en
Prevalence and prognostic valu ...... y: a prospective cohort study.
@nl
P2093
P50
P1433
P1476
Prevalence and prognostic valu ...... y: a prospective cohort study.
@en
P2093
Asa K Wallin
Dirk L Knol
Frans Verhey
Katharina Bürger
Luiza Spiru
Marcel M Verbeek
Marcel Olde Rikkert
Pieter Jelle Visser
Tuula Pirttila
P304
P356
10.1016/S1474-4422(09)70139-5
P50
P577
2009-06-10T00:00:00Z